Advice

following a full submission assessed under the orphan medicine process:

etelcalcetide (Parsabiv®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.

In a phase III study, etelcalcetide was at least as effective as another calcimimetic in reducing parathyroid hormone levels.

The submitting company did not present a sufficiently robust economic analysis to gain acceptance by the SMC.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Download detailed advice344KB (PDF)

Download

Medicine details

Medicine name:
etelcalcetide (Parsabiv)
SMC ID:
1262/17
Indication:
Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.
Pharmaceutical company
Amgen Ltd
BNF chapter
Nutrition and blood
Submission type
Full
Status
Not recommended
Date advice published
11 September 2017